Skip to main content

Hybridon Granted Patent on Circular Oligonucleotides For Antisense

NEW YORK, May 20-The antisense chemistry company Hybridon said today that it has been issued a U.S. patent for its class of novel circular oligonucleotides.

 

These oligonucleotides are designed so that a functional domain and a protective domain are linked together in a circular structure. As the functional domain binds to its target mRNA, the circular structure opens to inhibit target protein expression.

 

According to Hybridon, this structure improves stability and decreases non-specific interactions.

 

This second-generation technology is being developed for a range of antisense applications, including target validation, antinses drugs and diagnostic probes.

 

Hybridon's patent was issued by the U.S. Patent and Trade Office on May 7.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.